Table 1 |
|||
|
Genotype frequencies by treatment group |
|||
| Group |
|||
|
|
|||
| Gene/polymorphism |
Isoflavone |
Placebo |
P |
|
|
|||
| CYP17a |
|||
| TT |
32 (40%) |
33 (39%) |
|
| TC |
36 (44%) |
40 (47%) |
0.92 |
| CC |
13 (16%) |
12 (14%) |
|
| CYP19b |
|||
| GG |
21 (27%) |
28 (32%) |
|
| GT |
40 (51%) |
45 (52%) |
0.49 |
| TT |
18 (23%) |
14 (16%) |
|
| ESR1c |
|||
| CC |
17 (22%) |
19 (22%) |
|
| CT |
39 (51%) |
46 (53%) |
0.95 |
| TT |
21 (27%) |
22 (25%) |
|
|
|
|||
|
aCYP17 data not available for three and five women in the isoflavone and placebo groups, respectively. bCYP19 data not available for five and three women in the isoflavone and placebo groups, respectively. cESR1 data not available for seven and three women in the isoflavone and placebo groups, respectively. Percentages do not always add up to 100% because of rounding. |
|||
|
Atkinson et al. Breast Cancer Res 2004 6:R170 |
|||
